How to Play Gold Po...
Health Care: Health Services
Response Genetics Inc. (RGDX: NASDAQ)
$1.43 -0.08 | -5.30%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 18.74M | 22.64M | 21.28M | 9.07M |
| Cost of Sales | 9.95M | 11.37M | 10.00M | 5.34M |
| Gross Operating Profit | 8.79M | 11.28M | 11.28M | 3.73M |
| Selling, General, and Administrative Expenses | 13.85M | 15.27M | 14.09M | 10.46M |
| Research & Development | 2.13M | 1.32M | 1.61M | 2.29M |
| Operating Income before D & A (EBITDA) | -7.19M | -5.32M | -4.42M | -9.02M |
| Depreciation & Amortization | 470.06K | 366.70K | 465.69K | 385.43K |
| Interest Income | 27.00 | 149.00 | 682.00 | 22.26K |
| Other Income - Net | -14.00K | 0.00 | 221.80K | 49.72K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -7.67M | -5.68M | -4.66M | -9.34M |
| Interest Expense | 85.84K | 20.72K | 10.58K | 10.82K |
| Pre-Tax Income | -7.76M | -5.70M | -4.67M | -9.35M |
| Income Taxes | 0.00 | 0.00 | 1.26K | -4.79K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -7.76M | -5.70M | -4.67M | -9.34M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -7.76M | -5.70M | -4.67M | -9.34M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -7.76M | -5.70M | -4.67M | -9.34M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-7.76M | -5.70M | -4.67M | -9.34M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -7.76M | -5.70M | -4.67M | -9.34M |
| Basic EPS from Continuing Ops. | -0.29 | -0.30 | -0.26 | -0.70 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.29 | -0.30 | -0.26 | -0.70 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.29 | -0.30 | -0.26 | -0.70 |
| Basic Normalized Net Income/Share | -0.29 | -0.30 | -0.26 | -0.70 |
| EPS fr Continuing Ops. | -0.29 | -0.30 | -0.26 | -0.70 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.29 | -0.30 | -0.26 | -0.70 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.29 | -0.30 | -0.26 | -0.70 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.29 | -0.30 | -0.26 | -0.70 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with RGDX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- Userjaysan Portfolio 1
- Usercurry Portfolio 1
- Usercharlesl950 Portfolio 1
- UserWACKJDDUDE Portfolio 1
Latest RGDX Headlines from TheStreet
- Response Genetics, Inc. Announces Presentations At The American Society Of Clinical Oncology 2013 Annual Meeting 05.20.13 | 07:05 am
- Response Genetics, Inc. Announces Contract With Blue Shield Of California 05.16.13 | 07:05 am
- Response Genetics, Inc. Announces First Quarter 2013 Financial Results 05.14.13 | 07:05 am
- Response Genetics To Present At The 2013 UBS Global Healthcare Conference 05.08.13 | 07:05 am
- Response Genetics, Inc. To Release First Quarter 2013 Financial Results And Host Conference Call On May 14, 2013 05.06.13 | 07:05 am
- Response Genetics, Inc. Announces Fourth Quarter And Year-End 2012 Financial Results 03.21.13 | 07:03 am
- Response Genetics To Present At The 25th Annual ROTH Conference 03.12.13 | 07:03 am
- Response Genetics, Inc. To Release Fourth Quarter And Year-End 2012 Financial Results And Host Conference Call On March 21, 2013 03.07.13 | 07:03 am
- 5 Under-$10 Stocks Setting Up to Trade Higher 11.30.12 | 12:11 pm
- 5 Stocks With Big Insider Buying 09.19.12 | 12:09 pm
Press Releases for RGDX
- Response Genetics, Inc. To Offer Enhanced ALK Testing Program For Metastatic Lung Cancer Patients - Business Wire 06.28.12 | 08:06 am
- Response Genetics Announces Presentation Of Lung Cancer Study Results At 2012 American Society Of Clinical Oncology Annual Meeting - Business Wire 05.30.12 | 08:05 am
- Response Genetics, Inc. Announces First Quarter Financial Results - Business Wire 05.10.12 | 08:05 am
- Response Genetics, Inc. To Release First Quarter Financial Results And Host Conference Call On May 10, 2012 - Business Wire 05.04.12 | 08:05 am
- Response Genetics, Inc. Announces Year-End And Fourth Quarter Financial Results - Business Wire 03.27.12 | 08:03 am
- Response Genetics, Inc. Announces Appointment Of Stephanie Astrow, Ph.D., As Vice President, Research And Development - Business Wire 03.26.12 | 08:03 am
- Response Genetics, Inc. To Release Fourth Quarter And Full-Year 2011 Financial Results And Host Conference Call On March 27, 2012 - Business Wire 03.21.12 | 08:03 am
- Response Genetics Regains NASDAQ Compliance - Business Wire 02.21.12 | 07:02 am
- Response Genetics To Present At The 22nd Annual UBS Global Healthcare Services Conference - Business Wire 02.06.12 | 07:02 am
- Response Genetics Raises More Than $7.8 Million In Financing - Business Wire 02.02.12 | 07:02 am
Partner Headlines for RGDX
- Benzinga's Small Cap Movers for Friday November 30, 2012 - Benzinga 12.02.12 | 11:12 am
- Glaxo Increases Stake in RGDX - Analyst Blog - NASDAQ 09.18.12 | 09:09 pm
- Response Genetics: This Train Is About To Leave The Station - Seeking Alpha 02.16.12 | 09:02 am
- Response Genetics Stock Soars 31% On $7.8M Offering News - Seeking Alpha 02.03.12 | 08:02 am
- Biomarker Diagnostics Drive Personalized Medicine but Path to Market Still Rife With Hurdles - Seeking Alpha 07.07.10 | 07:07 am
- Three Promising Small-Cap Cancer Plays - Seeking Alpha 05.17.10 | 08:05 am
- Response Genetics: An Earnings Primer - Seeking Alpha 05.12.10 | 06:05 am
- UPDATE 1-Response Genetics inks deal with Glaxo, shares soar - Reuters 05.11.10 | 10:05 am
